A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients – ZAP2
Abstract Background Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of subchondral bone marrow lesions (BMLs) over 6 months in knee OA...
Main Authors: | Dawn Aitken, Laura L. Laslett, Guoqi Cai, Catherine Hill, Lyn March, Anita E. Wluka, Yuanyuan Wang, Leigh Blizzard, Flavia Cicuttini, Graeme Jones |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | BMC Musculoskeletal Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12891-018-2143-2 |
Similar Items
-
Zoledronic acid plus methylprednisolone zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial
by: Guoqi Cai, et al.
Published: (2019-10-01) -
Giant Cell Tumour Around Knee Managed by Curettage and Zoledronic Acid with Structural Support by Fibula Cortical Struts
by: Singaravadivelu V, et al.
Published: (2020-11-01) -
The associations between body and knee height measurements and knee joint structure in an asymptomatic cohort
by: Teichtahl Andrew J, et al.
Published: (2012-02-01) -
Associations between systemic bone mineral density and early knee cartilage changes in middle-aged adults without clinical knee disease: a prospective cohort study
by: Andrew J. Teichtahl, et al.
Published: (2017-05-01) -
KARAOKE: Krill oil versus placebo in the treatment of knee osteoarthritis: protocol for a randomised controlled trial
by: L. L. Laslett, et al.
Published: (2020-01-01)